223 related articles for article (PubMed ID: 24780128)
1. Myocardial and anti-inflammatory effects of chronic bosentan therapy in monocrotaline-induced pulmonary hypertension.
Fontoura D; Oliveira-Pinto J; Tavares-Silva M; Leite S; Vasques-Nóvoa F; Mendes-Ferreira P; Lourenço AP; Leite-Moreira AF
Rev Port Cardiol; 2014 Apr; 33(4):213-22. PubMed ID: 24780128
[TBL] [Abstract][Full Text] [Related]
2. Haemodynamic and neuroendocrine effects of tezosentan in chronic experimental pulmonary hypertension.
Lourenço AP; Vasques-Nóvoa F; Oliveira-Pinto J; Fontoura D; Roncon-Albuquerque R; Leite-Moreira AF
Intensive Care Med; 2012 Jun; 38(6):1050-60. PubMed ID: 22349420
[TBL] [Abstract][Full Text] [Related]
3. Role of oxidative stress, inflammation, nitric oxide and transforming growth factor-beta in the protective effect of diosgenin in monocrotaline-induced pulmonary hypertension in rats.
Ahmed LA; Obaid AA; Zaki HF; Agha AM
Eur J Pharmacol; 2014 Oct; 740():379-87. PubMed ID: 25062790
[TBL] [Abstract][Full Text] [Related]
4. Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats.
Clozel M; Hess P; Rey M; Iglarz M; Binkert C; Qiu C
Exp Biol Med (Maywood); 2006 Jun; 231(6):967-73. PubMed ID: 16741032
[TBL] [Abstract][Full Text] [Related]
5. The orally active nonpeptide selective endothelin ETA receptor antagonist YM598 prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats.
Yuyama H; Fujimori A; Sanagi M; Koakutsu A; Sudoh K; Sasamata M; Miyata K
Eur J Pharmacol; 2004 Aug; 496(1-3):129-39. PubMed ID: 15288584
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension.
Iglarz M; Landskroner K; Bauer Y; Vercauteren M; Rey M; Renault B; Studer R; Vezzali E; Freti D; Hadana H; Schläpfer M; Cattaneo C; Bortolamiol C; Weber E; Whitby BR; Delahaye S; Wanner D; Steiner P; Nayler O; Hess P; Clozel M
J Cardiovasc Pharmacol; 2015 Nov; 66(5):457-67. PubMed ID: 26230396
[TBL] [Abstract][Full Text] [Related]
7. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil.
Mouchaers KT; Schalij I; de Boer MA; Postmus PE; van Hinsbergh VW; van Nieuw Amerongen GP; Vonk Noordegraaf A; van der Laarse WJ
Eur Respir J; 2010 Oct; 36(4):800-7. PubMed ID: 20351034
[TBL] [Abstract][Full Text] [Related]
8. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats.
Hill NS; Warburton RR; Pietras L; Klinger JR
J Appl Physiol (1985); 1997 Oct; 83(4):1209-15. PubMed ID: 9338430
[TBL] [Abstract][Full Text] [Related]
9. Genistein, a phytoestrogen, attenuates monocrotaline-induced pulmonary hypertension.
Homma N; Morio Y; Takahashi H; Yamamoto A; Suzuki T; Sato K; Muramatsu M; Fukuchi Y
Respiration; 2006; 73(1):105-12. PubMed ID: 16432296
[TBL] [Abstract][Full Text] [Related]
10. Activation of the right ventricular endothelin (ET) system in the monocrotaline model of pulmonary hypertension: response to chronic ETA receptor blockade.
Jasmin JF; Cernacek P; Dupuis J
Clin Sci (Lond); 2003 Dec; 105(6):647-53. PubMed ID: 12823096
[TBL] [Abstract][Full Text] [Related]
11. [Effects of rosuvastatin on monocrotaline-induced pulmonary artery hypertension in rats].
Li XL; Guan RJ; Xu QH; Wu ZY
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Mar; 39(3):247-53. PubMed ID: 21609531
[TBL] [Abstract][Full Text] [Related]
12. Effects of selective and unselective endothelin-receptor antagonists on prostacyclin synthase gene expression in experimental pulmonary hypertension.
Schroll S; Arzt M; Sebah D; Stoelcker B; Luchner A; Budweiser S; Blumberg FC; Pfeifer M
Scand J Clin Lab Invest; 2008; 68(4):270-6. PubMed ID: 18612919
[TBL] [Abstract][Full Text] [Related]
13. Palosuran treatment effective as bosentan in the treatment model of pulmonary arterial hypertension.
Pehlivan Y; Dokuyucu R; Demir T; Kaplan DS; Koc I; Orkmez M; Turkbeyler IH; Ceribasi AO; Tutar E; Taysi S; Kisacik B; Onat AM
Inflammation; 2014 Aug; 37(4):1280-8. PubMed ID: 24604341
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effects of γ-aminobutyric acid on right ventricular pressure and pulmonary vascular remodeling in experimental pulmonary hypertension.
Suzuki R; Maehara R; Kobuchi S; Tanaka R; Ohkita M; Matsumura Y
Life Sci; 2012 Oct; 91(13-14):693-8. PubMed ID: 22542556
[TBL] [Abstract][Full Text] [Related]
15. Preventive effects of raloxifene, a selective estrogen receptor modulator, on monocrotaline-induced pulmonary hypertension in intact and ovariectomized female rats.
Nishida M; Hasegawa Y; Tanida I; Nakagawa E; Inaji H; Ohkita M; Matsumura Y
Eur J Pharmacol; 2009 Jul; 614(1-3):70-6. PubMed ID: 19379725
[TBL] [Abstract][Full Text] [Related]
16. Synergistic therapeutic effects of 2-methoxyestradiol with either sildenafil or bosentan on amelioration of monocrotaline-induced pulmonary hypertension and vascular remodeling.
Tofovic SP; Jones TJ; Bilan VP; Jackson EK; Petrusevska G
J Cardiovasc Pharmacol; 2010 Nov; 56(5):475-83. PubMed ID: 20881615
[TBL] [Abstract][Full Text] [Related]
17. Percutaneous Carbon Dioxide Treatment Using a Gas Mist Generator Attenuates the Development of Right Ventricular Dysfunction in Monocrotaline-induced Pulmonary Hypertensive Rats.
Yamaguchi T; Izumi Y; Yamazaki T; Nakamura Y; Sano S; Shiota M; Miura K; Iwao H; Yoshiyama M
Osaka City Med J; 2015 Jun; 61(1):31-41. PubMed ID: 26434103
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension.
Kosanovic D; Kojonazarov B; Luitel H; Dahal BK; Sydykov A; Cornitescu T; Janssen W; Brandes RP; Davie N; Ghofrani HA; Weissmann N; Grimminger F; Seeger W; Schermuly RT
Respir Res; 2011 Jun; 12():87. PubMed ID: 21699729
[TBL] [Abstract][Full Text] [Related]
19. Myocardial dysfunction and neurohumoral activation without remodeling in left ventricle of monocrotaline-induced pulmonary hypertensive rats.
Lourenço AP; Roncon-Albuquerque R; Brás-Silva C; Faria B; Wieland J; Henriques-Coelho T; Correia-Pinto J; Leite-Moreira AF
Am J Physiol Heart Circ Physiol; 2006 Oct; 291(4):H1587-94. PubMed ID: 16679394
[TBL] [Abstract][Full Text] [Related]
20. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.
Schäfer S; Ellinghaus P; Janssen W; Kramer F; Lustig K; Milting H; Kast R; Klein M
Cardiovasc Res; 2009 Apr; 82(1):30-9. PubMed ID: 19131365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
